Seeking Alpha

Sarepta Therapeutics (SRPT) files with the SEC an at-the-market equity offering sales agreement...

Sarepta Therapeutics (SRPT) files with the SEC an at-the-market equity offering sales agreement with Citadel Securities to sell, from time to time, up to $40M of its common stock. Shares -2% AH.
Comments (2)
  • tnientimp
    , contributor
    Comments (6) | Send Message
     
    The key is their potential block buster drug not $40m of their stock. While there will be some dilution it gives them some financial flexibility. Let's hope they use it wisely.
    5 Sep 2012, 12:53 AM Reply Like
  • linckster
    , contributor
    Comments (6) | Send Message
     
    Plucky. Going for all the marbles, seemingly, which is hardly a bad sign.
    5 Sep 2012, 01:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector